Advertisement

Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 6815 | Ordered by Date (descending)
1 2 3 ... 67 68 69  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
S-Biomedic–SEVERAL: investment, 201902 financing round Series A 2nd closing €2m from new investor DSM Venturing + existing investor investiere.ch 2019-02-18
Arvelle Therapeutics–NovaQuest Capital: investment, 201902 financing round Series A totalling $180m incl investor NovaQuest Capital Management 2019-02-14
Arvelle Therapeutics–Sam Brown: public relations, 201902 service existent by Sam Brown Inc 2019-02-14
Arvelle Therapeutics–SEVERAL: investment, 201902 financing round Series A $180m with global investor syndicate 2019-02-14
Arvelle Therapeutics–SK Group: cenobamate, 201902– license excl for Europe $110m upfront + $430m milestones + royalties from SK Biopharmaceuticals 2019-02-14
Novartis–AbCellera: therapeutic antibodies, 201902– collab use of AbCellera technology + screening for up to ten targets 2019-02-14
Auris Health–JnJ: investment, 201902 acquisition $3.4b in cash + $2.35b milestones by Ethicon Inc 2019-02-13
CiToxLab–Charles River: investment, 201902– acquisition $448m in cash BINDING OFFER SIGNED 2019-02-13
Boehringer–IBM: blockchain technology, 201902– collab to integrate blockchain technology into clinical trials of BI Canada + IBM Canada 2019-02-12
Grey Wolf Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Canaan Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–SEVERAL: investment, 201902 financing round Series A £10m with Andera Partners + Canaan 2019-02-11
Symrise–SEVERAL: investment, 201902 capital increase €400m with 5.614m new shares at €71.25/share to fund acquisition of ADF/IDF 2019-02-08
Fluidigm–Indica Labs: digital pathology software, 201902– collab co-promotion of HALO image analysis s/w with Hyperion Imaging System 2019-02-07
HiberCell–6 Dimensions Capital: investment, 201902 financing round Series A totalling $60.75m incl co-investor 6 Dimensions Capital 2019-02-07
HiberCell–ARCH Venture: investment, 201902 financing round Series A totalling $60.75m incl lead investor ARCH Venture Partners 2019-02-07
HiberCell–Celgene: investment, 201902 financing round Series A totalling $60.75m incl co-investor Celgene Corp 2019-02-07
HiberCell–New York (govt): investment, 201902 financing round Series A totalling $60.75m incl co-investor NYC Life Sciences Fund 2019-02-07
HiberCell–SEVERAL: investment, 201902 financing round Series A $60.75m led by ARCH Venture Partners 2019-02-07
Invisible Sentinel–Mérieux: investment, 201902 acquisition $75m in cash by bioMérieux 2019-02-07
MacroGenics–MacDougall Biomedical Communications: public relations, 201902 service existent by MacDougall 2019-02-06
Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research 2019-02-06
Bruker Corp–Genedata: drug screening software, 201902 collab product integration Bruker new Ready-to-Run partner 2019-02-05
Lilly–ProteoNic: rec protein production technology, 201902– license non-excl €na to use 2G UNic technology to boost rec protein production 2019-02-05
Roche–Xencor: cancer immunotherapy, 201901– collab developm + commerc ww $120m upfront + milestones + profit share IL-15 cytokine drugs Genentech 2019-02-05
Argen-X–Halozyme: drug delivery technology, 201901– collab + license agreem ww for Enhanze technology $30m upfront + milestones + royalties 2019-02-04
ADF/IDF–Symrise: investment, 201901– acquisition $900m by Symrise ANNOUNCED 2019-01-31
JnJ–MeiraGTx: gene therapy, 201901– collab r+d + license ww excl $100m upfront + milestones + funding + 20% royalties for inherited retinals diases 2019-01-31
Dewpoint Therapeutics–6 Dimensions Capital: investment, 201901 financing round Series A totallling $60m incl co-investor 6 Dimensions Capital 2019-01-30
Dewpoint Therapeutics–Alexandria Real Estate: investment, 201901 financing round Series A totallling $60m incl co-investor Alexandria Ventures 2019-01-30
Dewpoint Therapeutics–Bayer: investment, 201901 financing round Series A totallling $60m incl co-investor Leaps by Bayer 2019-01-30
Dewpoint Therapeutics–EcoR1 Capital: investment, 201901 financing round Series A totallling $60m incl co-investor EcoR1 Capital 2019-01-30
Dewpoint Therapeutics–Polaris Partners: investment, 201901 financing round Series A totallling $60m incl lead investor Polaris Partners 2019-01-30
Dewpoint Therapeutics–Samsara BioCapital: investment, 201901 financing round Series A totallling $60m incl co-investor Samsara BioCapital 2019-01-30
Dewpoint Therapeutics–SEVERAL: investment, 201901 financing round Series A $60m led by Polaris Partners 2019-01-30
Labcyte–Danaher: investment, 201901 acquisition of Labcyte by Beckman Coulter Life Sciences 2019-01-30
Biodesix–MRM Proteomics: MALDI-TOF mass spectrometry, 201901– collab use of iMALDI technologies to advance blood-based lung cancer test 2019-01-28
Horizon Discovery–Rutgers Univ: gene editing technology, 201901– collab strategic developm + excl license option for base editing technology 2019-01-28
Grifols–Rigel: fostamatinib, 201901– collab + license $30m upront + $297.5m milestones + royalties all indications in Europe + Turkey 2019-01-23
CRISPR Therapeutics–Minapharm: gene transfer technology, 201901– collab + license €na with ProBioGen to develop in vivo delivery technology for CRISPR 2019-01-22
Medison Pharma–Alnylam: RNAi therapeutics, 201901– commcercialisation excl of Onpattro + other RNAi drugs from Alnylam in Israel 2019-01-21
Stemline Therapeutics–SEVERAL: investment, 201901 public offering $80m+$12m with 8.9m+1.3m shares common stock at $9/share 2019-01-18
Acceleron Pharma–SEVERAL: investment, 201901 public offering $230m net $215.8m with 5.4m shares common stock at $43/share 2019-01-16
Nanobiotix–RooneyPartners: public relations, 201901 service existent US media relations by RooneyPartners 2019-01-16
Nanobiotix–SEVERAL: investment, 201901– filing of Form F-1 for registered public offering of shares + ADSs in US conditions to be determined later 2019-01-16
Boehringer–Bioharmony Therapeutics: antibiotics, 201901– collab developm of bateriophage lysins 2019-01-15
Life Biosciences–SEVERAL: investment, 201901 financing round Series B $50m 2019-01-15
Alnylam–SEVERAL: investment, 201901 public offering $387.5m with 5m shares common stock at $77.5/share 2019-01-14
AMETEK–SEVERAL: credit, 201901 private placement $100m senior notes 4.32% due 202712 2019-01-14
ATUM–Solentim: cell line development technology, 201901– collab product integration of VIPS hardware + Leap-In Transposase expression technology 2019-01-14
Cell Signaling Technology–Omni Life Science: cell research instruments, 201901– distribution of OLS’ CERO + CESY instruments by Bioké in Benelux 2019-01-14
Merck (DE)–Roche: biochemical reagents, 201901–2025 distribution extension ww excl of Roche biochemical reagents portfolio 2019-01-14
Charles River–Atomwise: drug discovery software, 201901– collab alliance giving clients accesss to AI-powered structure-based drug design s/w 2019-01-11
Affimed–JPMorgan Chase: investor conference, 201901 supply service Affimed presents at JP Morgan Healthcare Conference 2019 2019-01-10
Evotec–JPMorgan Chase: investor conference, 201901 supply service Evotec presents at JP Morgan Healthcare Conference 2019 2019-01-10
Tecan–JPMorgan Chase: investor conference, 201901 supply service Tecan Group presents at JP Morgan Healthcare Conference 2019 2019-01-10
UroGen–JPMorgan Chase: investor conference, 201901 supply service UroGen Pharma presents at JP Morgan Healthcare Conference 2019 2019-01-10
Acorda–JPMorgan Chase: investor conference, 201901 supply service Acorda presents at JP Morgan Healthcare Conference 2019 2019-01-09
Agenus–JSR Corp: cell line development, 201901– collab expansion license to use Selexis’ SUREtechnology for production of therapeutic proteins 2019-01-09
Denali Therapeutics–Sirion Biotech: gene delivery technology, 201901– license + collab develop AAV vectors for CNS diseases that could cross BBB 2019-01-09
Editas Medicine–JPMorgan Chase: investor conference, 201901 supply service Editas presents at JP Morgan Healthcare Conference 2019 2019-01-09
Galapagos–JPMorgan Chase: investor conference, 201901 supply service Galapagos presents at JP Morgan Healthcare Conference 2019 2019-01-09
Orchard Therapeutics–JPMorgan Chase: investor conference, 201901 supply service Orchard presents at JP Morgan Healthcare Conference 2019 2019-01-09
Senolytic Therapeutics–Life Biosciences: investment, 201901 acquisition of Senolytic by Life Biosciences 2019-01-09
Allogene Therapeutics–JPMorgan Chase: investor conference, 201901 supply service Allogene presents at JP Morgan Healthcare Conference 2019 2019-01-08
Danaher–JPMorgan Chase: investor conference, 201901 supply service Danaher presents at JP Morgan Healthcare Conference 2019 2019-01-08
GreenLight Biosciences–SEVERAL: investment, 201901 financing round first closing $50m 2019-01-08
Bruker Corp–JPMorgan Chase: investor conference, 201901 supply service Bruker presents at JP Morgan Healthcare Conference 2019 2019-01-07
Exscientia–Celgene: investment, 201901 financing round Series B totalling $26m incl new investor Celgene Corp 2019-01-07
Exscientia–Evotec: investment, 201901 financing round Series B totalling $26m incl $6m from existing investor Evotec AG 2019-01-07
Exscientia–GT Healthcare Capital Partners: investment, 201901 financing round Series B totalling $26m incl new investor GT Healthcare Capital Partners 2019-01-07
Exscientia–SEVERAL: investment, 201901 financing round Series B $26m incl Celgene Corp + GT Heallthcare Capital Partners + Evotec 2019-01-07
Keros Therapeutics–SEVERAL: investment, 201901 financing round Series B $23m incl Pontifax + Arkin Bioventures + Partners Innovation Fund 2019-01-07
Loxo Oncology–Lilly: investment, 201901–201902 acquisition cash tender offer $8b for $235/share 2019-01-07
Myriad–JPMorgan Chase: investor conference, 201901 supply service Myrad Genetics presents at JP Morgan Healthcare Conference 2019 2019-01-07
N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen 2019-01-07
Waters–JPMorgan Chase: investor conference, 201901 supply service Waters presents at JP Morgan Healthcare Conference 2019 2019-01-07
Ribon Therapeutics–Celgene: investment, 201901 financing round Series B totalling $65m incl new + co-investor Celgene Corp 2019-01-04
Ribon Therapeutics–Column Group: investment, 201901 financing round Series B totalling $65m incl existing + co-investor The Column Group 2019-01-04
Ribon Therapeutics–Deerfield Management: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Deerfield Management 2019-01-04
Ribon Therapeutics–Euclidean Capital: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Euclidean Capital 2019-01-04
Ribon Therapeutics–JnJ: investment, 201901 financing round Series B totalling $65m incl new + co-investorJJDC 2019-01-04
Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund 2019-01-04
Ribon Therapeutics–Osage Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Osage University Partners 2019-01-04
Ribon Therapeutics–SEVERAL: investment, 201901 financing round Series B $65m led by Novartis Venture Fund 2019-01-04
Ribon Therapeutics–Takeda: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Takeda Ventures 2019-01-04
Ribon Therapeutics–US Venture Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor US Venture Partners 2019-01-04
Sana Biotechnology–ARCH Venture: investment, 201901 founding investors ARCH Venture Partners + F-Prime Capital + Flagship Pioneering 2019-01-04
Sana Biotechnology–F-Prime: investment, 201901 founding investors ARCH Venture Partners + F-Prime Capital + Flagship Pioneering 2019-01-04
Sana Biotechnology–Flagship Pioneering: investment, 201901 founding investors ARCH Venture Partners + F-Prime Capital + Flagship Pioneering 2019-01-04
Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
Alphabet–SEVERAL: investment, 201901 financing round $1b of Verily Life Sciences led by Silver Lake 2019-01-03
Celgene–BMS: investment, 201901– acquisition merger $74b in cash + shares with BMS owners owning 69% + Celgene owners 31% post-closing ANNOUNCED 2019-01-03
Fujifilm–Zyme Communications: public relations, 201901 service existent for Fujifilm Irvine Scientific by Zyme 2019-01-02
Murdoch Univ–Bruker Corp: mass spectrometer, 2018 supply ordered FIA-MRMS system 2018-12-31
Murdoch Univ–Bruker Corp: mass spectrometer, 2018 supply ordered impact-II UHR-QTOF LC-MS/MS system 2018-12-31
1 2 3 ... 67 68 69  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture BIO Deutschland German Biotech Days 2019 Würzburg 600x60px

» top